NASDAQ:GERN
Geron Corporation Stock News
$3.87
+0.140 (+3.75%)
At Close: May 07, 2024
Bristol Myers' (BMY) Opdivo Combos Get FDA Nod for ESCC
07:03pm, Monday, 30'th May 2022 Zacks Investment Research
Bristol Myers (BMY) secures an FDA approval for two Opdivo-based regimens as the first-line treatment of unresectable advanced or metastatic esophageal squamous cell carcinoma.
Regeneron's (REGN) Evkeeza Positive in Late-Stage Study
04:26pm, Monday, 23'rd May 2022 Zacks Investment Research
Regeneron (REGN) announces positive data on a phase III study on cholesterol treatment Evkeeza.
Novartis (NVS) Cosentyx Gets Positive CHMP Opinion for JIA
03:46pm, Monday, 23'rd May 2022 Zacks Investment Research
Novartis (NVS) Cosentyx gets a positive CHMP recommendation for the indication of juvenile idiopathic arthritis.
Dynavax (DVAX) Up as EMA Accepts Valneva's COVID-19 Vaccine MAA
04:53pm, Friday, 20'th May 2022 Zacks Investment Research
Dynavax (DVAX) gains as the EMA accepts partner Valneva's MAA for COVID-19 vaccine.
Endo (ENDP) Crashes 46.54% as it Looks to Restructure Debt
04:15pm, Thursday, 19'th May 2022 Zacks Investment Research
Endo (ENDP) plunges on reports of negotiations with its lenders and senior bondholders about a possible restructuring of more than $8 billion of debt.
Geron to Present at the H.C. Wainwright Global Investment Conference
04:30pm, Tuesday, 17'th May 2022
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignanci
Bristol Myers (BMY) Phase III CheckMate -901 Study Disappoints
03:33pm, Tuesday, 17'th May 2022 Zacks Investment Research
Bristol Myers (BMY) phase III CheckMate -901 study fails to meet the primary endpoint of overall survival in patients with untreated unresectable or metastatic urothelial cancer.
Gilead (GILD) HIV Studies Removed From FDA's Clinical Hold
03:30pm, Tuesday, 17'th May 2022 Zacks Investment Research
Gilead (GILD) studies evaluating injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP) removed from hold.
Why Geron Stock Is Soaring Today
04:21pm, Tuesday, 10'th May 2022 The Motley Fool
Investors are reacting positively to the company's Q1 update.
Why Geron Stock Is Soaring Today
12:21pm, Tuesday, 10'th May 2022
Investors are reacting positively to the company's Q1 update.
Geron (GERN) Q1 2022 Earnings Call Transcript
06:09am, Tuesday, 10'th May 2022 The Motley Fool
GERN earnings call for the period ending March 31, 2022.
Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates
09:55pm, Monday, 09'th May 2022 Zacks Investment Research
Geron (GERN) delivered earnings and revenue surprises of 18.18% and 23%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Geron Corporation (GERN) CEO John Scarlett on Q1 2022 Results - Earnings Call Transcript
07:59pm, Monday, 09'th May 2022
Geron Corporation. (NASDAQ:GERN ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Aron Feingold - VP of Investor Relations and Corporate Communications Olivia Bloom - Exec
Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates
07:33pm, Monday, 09'th May 2022
Geron (GERN) delivered earnings and revenue surprises of 18.18% and 23%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Xoma (XOMA) Reports Q1 Loss, Misses Revenue Estimates
12:55pm, Thursday, 05'th May 2022 Zacks Investment Research
Xoma (XOMA) delivered earnings and revenue surprises of 5.88% and 12.73%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
